Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect of cancer treatment.
• Current treatments for CIPN lack efficacy and have significant side effects, necessitating novel therapeutic strategies.
• Aberrant neuronal excitability, particularly in dorsal root ganglion (DRG) neurons, underlies neuropathic pain, with Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels implicated.

Purpose of the Study:

• To investigate the role of HCN channels in CIPN pathogenesis.
• To identify specific HCN channel isoforms involved in oxaliplatin-induced neuropathy.
• To evaluate the therapeutic potential of selective HCN channel inhibitors for CIPN treatment.

Main Methods:

• Utilized an oxaliplatin-induced rat model of CIPN.
• Assessed DRG neuron function and HCN channel expression.
• Examined the efficacy of MEL57A, a selective HCN1 inhibitor, on neuropathic pain behaviors.
• Monitored for cardiac side effects associated with HCN channel inhibition.

Main Results:

• Demonstrated a gain of function in HCN currents in DRG neurons from oxaliplatin-treated rats.
• Observed downregulation of HCN2 expression and upregulation of MirP1.
• MEL57A significantly reduced hyperalgesia and allodynia in the CIPN rat model.
• No cardiac adverse effects were observed with MEL57A treatment.

Conclusions:

• HCN1 channels play a critical, disease-specific role in the development of CIPN.
• Selective inhibition of HCN1 channels offers a promising therapeutic approach for managing CIPN.
• HCN1-selective inhibitors represent a potential new class of pain medications with improved efficacy and safety profiles for cancer patients.